Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0777 · 4 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Drug |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| MK0777 | DRUG | - |
| Comparator: placebo (unspecified) | DRUG | Duration of Treatment: 4 weeks |
| Placebo (unspecified) | DRUG | matching placebo |
Inclusion Criteria: * Have been diagnosed with Generalized Anxiety Disorder * Women of childbearing potential must use a double-barrier methods of contraception and must have a negative blood pregnancy test at the beginning of the study Exclusion Criteria: * History of drug or alcohol abuse * Hav...
Top 5 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Definium Therapeutics, Inc. | DFTX | 2 | PHASE3 | DT120 |
| Vistagen Therapeutics, Inc. | VTGN | 3 | PHASE3 | Fasedienol |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | VQW-765 |
| AbbVie, Inc. | ABBV | 1 | PHASE2 | ABBV-932 |
| Psyence Biomedical Ltd. | PBM | 1 | PHASE2 | Psilocybin therapy |
MK0777 is an investigational small molecule developed by Merck & Company, Inc. for the treatment of anxiety disorders, including generalized anxiety disorder (GAD). It has been studied in adult outpatients aged 18 years and older. MK0777 remains in clinical development and is not approved for any indication.
MK0777 is developed by Merck & Company, Inc., which trades under the ticker MRK. Merck sponsored the Phase 2 clinical program evaluating MK0777 in generalized anxiety disorder and other anxiety disorders. The compound is an investigational asset within Merck's psychiatry therapeutic area.
MK0777 is in Phase 2 clinical development. All four of its listed trials are Phase 2 studies, and all have completed. The program enrolled a total of 321 participants across these trials. MK0777 is investigational and has not been approved by the FDA for generalized anxiety disorder or any other indication.
MK0777 has been evaluated in four completed Phase 2 trials: NCT00703833, NCT00546624, NCT00543920, and NCT00539578. These studies enrolled 51, 38, 60, and 270 participants respectively, and all were conducted in adults aged 18 years and older with generalized anxiety disorder or anxiety disorders.
MK0777 is a small molecule being studied for anxiety disorders, including generalized anxiety disorder. It was evaluated in randomized, double-blind Phase 2 trials, including a study comparing MK0777 gel extrusion module (GEM) at 1.5 mg twice daily to 4.5 mg twice daily versus lorazepam in generalized anxiety disorder.
A total of 321 participants were enrolled across the completed Phase 2 trials of MK0777. The largest study, NCT00539578, enrolled 270 patients with generalized anxiety disorder. The other trials enrolled 51, 60, and 38 participants. All studies required participants to be at least 18 years of age.